1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 27,200 | 28,000 | 30.12.25 | |
| 0,000 | 0,000 | 30.12.25 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:10 | Spyre Therapeutics: Biotech-Aktie mit Potenzial | 593 | sharedeals.de | Die Biotechnologiebranche ist geprägt von einem Spannungsfeld zwischen wissenschaftlicher Innovationskraft und der oft fragilen finanziellen Lage vieler Unternehmen. Umso bemerkenswerter sind Fälle... ► Artikel lesen | |
| 17.12.25 | Mizuho initiates Spyre Therapeutics stock with Outperform rating | 4 | Investing.com | ||
| 17.12.25 | Spyre Therapeutics: Mizuho startet Coverage mit "Outperform" und sieht 60 % Potenzial | 2 | Investing.com Deutsch | ||
| 05.12.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 3 | GlobeNewswire (USA) | ||
| 01.12.25 | Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential | 3 | Investing.com | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 04.11.25 | Spyre Therapeutics GAAP EPS of -$0.15 beats by $0.61 | 6 | Seeking Alpha | ||
| 04.11.25 | Spyre Therapeutics reports positive interim data for IBD drug SPY003 | 2 | Investing.com | ||
| 04.11.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody | 60 | GlobeNewswire (Europe) | SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (a4ß7 +... ► Artikel lesen | |
| 04.11.25 | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 | 1 | GlobeNewswire (USA) | ||
| 15.10.25 | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million | 1 | GlobeNewswire (USA) | ||
| 14.10.25 | Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing | 1 | RTTNews | ||
| 14.10.25 | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10.25 | Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M | 1 | Seeking Alpha | ||
| 14.10.25 | Spyre Therapeutics legt Preis für Aktienangebot auf 18,50 US-Dollar fest | 1 | Investing.com Deutsch | ||
| 14.10.25 | Spyre Therapeutics prices public offering at $18.50 per share | 2 | Investing.com | ||
| 14.10.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 13.10.25 | Spyre Therapeutics announces public offering of common stock and pre-funded warrants | 1 | Seeking Alpha |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 26,800 | +1,52 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 90,00 | +4,65 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas | Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN rapamycin for... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 36,000 | +1,69 % | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| LENZ THERAPEUTICS | 16,000 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ) in South Korea for the Treatment of Presbyopia | SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,520 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 77,81 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 36,290 | +2,23 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,13 | -0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,88 | -0,55 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| IMMUNOME | 21,480 | +1,42 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ARCELLX | 65,20 | +2,52 % | Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset | ||
| ADMA BIOLOGICS | 18,240 | -0,65 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,560 | +1,88 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,460 | +1,32 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen | |
| NURIX THERAPEUTICS | 18,970 | -0,26 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,41 % bei einem Aktienkurs von 28,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.